Skip to main content
PMC home page
Chinese Medicine logoLink to Chinese Medicine
. 2020 Sep 17;15:99. doi: 10.1186/s13020-020-00380-4

Direct and indirect therapeutic effect of traditional Chinese medicine as an add-on for non-proliferative diabetic retinopathy: a systematic review and meta-analysis

Xuedong An 1,2,#, De Jin 1,2,#, LiYun Duan 1,2, Shenghui Zhao 1,3, Rongrong Zhou 1,2, Fengmei Lian 1,✉, Xiaolin Tong 1,✉
PMCID: PMC7499984  PMID: 32963587

Abstract

Background

Diabetic retinopathy (DR) is the leading cause of blindness in many countries. The current treatment for non-proliferative DR (NPDR) using Western medicine (WM) alone is insufficient. At present, the combination of NPDR treatment with traditional Chinese medicine (TCM) and WM is universally applied. We aimed to evaluate the effectiveness and safety of TCM as an add-on for NPDR using a systematic review and meta-analysis.

Method

Data from randomized controlled trials (RCTs) of TCM for NPDR treatment along with WM before July 6, 2019, were collected from the China National Knowledge Infrastructure, Wanfang Database, China Biomedical Database, Pubmed, Embase, and Cochrane Library. Relevant data were extracted by two reviewers. I2 statistics was adopted to appraise heterogeneity. If I2 < 50% the fixed-effects model was employed, otherwise a random-effect model was employed. (PROSPERO: CRD42019134947)

Result

Eighteen RCTs (1522 patients) were included based on the inclusion and exclusion criteria. The results showed that compared with WM alone, TCM (including Compound Xueshuantong Capsule, Qiming Granule, and others) combined with WM for NPDR could improve the overall effiicacy [n = 1686, RR 1.24 (1.18,1.30), P < 0.00001, I2 = 0%], and reduce the influence of risk factors related to NPDR, such as glycated hemoglobin level [n = 360, MD − 0.85 (− 1.28, − 0.41), P = 0.0001, I2 = 72%], triglyceride (P < 0.00001), and total cholesterol (P = 0.0008). Moreover, no serious adverse events were reported.

Conclusion

Compared with WM alone, TCM + WM could significantly improve NPDR and also reduce the correlation levels of risk factors, such as hyperglycemia, dyslipidemia. However, the small sample included in the study might lead to a publication bias, and therefore, our results should be treated with caution.

Keywords: Traditional Chinese medicine, Additional drugs, Non-proliferative diabetic retinopathy, Meta-analysis, Direct treatment, Indirect treatment

Background

According to the International Diabetes Federation, the number of patients with diabetes mellitus (DM) worldwide has reached 415 million, and by 2040, the total number of patients will exceed 600 million. In China, the prevalence rate of DM has increased from 0.67% in 1980 to 10.4% in 2013 [1], and complications related to DM will lead to greater economic and social burden in the future. Complications of DM include macrovascular complications (i.e. cardiovascular disease, stroke), microvascular complications (i.e. diabetic nephropathy, diabetic retinopathy (DR), and diabetic peripheral neuropathy). Among them, DR is a continuous process of microcirculation and lesion development. According to the American Academy of Ophthalmology Clinical Guidelines in 2006, DR is mainly divided into non-obvious DR, non-proliferative DR (NPDR), and proliferative DR (PDR), and is often accompanied by diabetic macular edema (DME). The quality of life, psychology, and social behavior are impaired in patients with PDR, incurring increased medical expenses [2]. Vision loss can also occur in the late stage of DME or PDR, with DR being one of the major causes of blindness in many countries [3].

There are many factors involved in the pathogenesis of DR: disease course, family inheritance, hyperglycemia, hyperlipemia, or hypertension [4, 5]. For the treatment of DR, the most important factor is lowering of blood sugar levels. Studies have shown that when glycosylated hemoglobin (HbAlc) is reduced by 10% from baseline (such as 10% to 9%), the progression of DR is reduced by 43% [6]. As demonstrated by the United Kingdom Prospective Diabetes Study, patients with tightly controlled blood pressure have a significant protective effect on DR progression [7]. Hyperlipidemia is associated with an increased risk of DR in Chinese patients with T2DM, suggesting that control of blood lipids may reduce the risk of DR [8]. In the non-proliferative phase, the main treatments are oral medications, including calcium dobesilate (CD), intestinal kininogenase, and large doses of compound danshen dripping pills, while in the proliferative phase, laser surgery, and anti-vascular endothelial growth factor (VEGF) are needed. However, clinical research shows that current treatment, such as oral WM, still have certain drawbacks, are not suitable for all patients, and the effects are not significant. Laser surgery is a destructive treatment that only prevents the occurrence of blindness but does not improve the vision and fundus lesions in general, despite a recent trial that showed improvement of vision in some patients [9]. Even after VEGF injections, a relatively high proportion of patients (46%) may still require local or grid laser treatment [10].

Traditional Chinese medicine (TCM) has been used for prevention and treatment of chronic diseases for nearly 2000 years and has an indelible contribution. Significant progress has been made in the treatment of DM and its complications. Many studies have shown that Jiangtang Tiaozhi Fang can effectively reduce the levels of blood sugar and lipids [11]. Further, Compound Danshen Dripping Pills are used to treat NPDR [12]. Nowadays, the combination of TCM and WM is more common in clinical practice, which is also applied to NPDR. Randomized clinical trials (RCTs) have shown that this combination is feasible and has good curative effects [12]. However, there is currently no systematic review to prove its safety and effectiveness, and there is still a lack of high-level evidence. Therefore, we systematically evaluated the efficacy and safety of TCM as an additional drug (add-on) for the treatment of NPDR, in order to provide high-level, referenceable evidence for the selection of clinical drugs.

Methods

This study was conducted and reported in accordance with the Preferred Reporting Project (PRISMA) guidelines for systematic reviews and meta-analysis [13]. The PROSPERO registration number is CRD42019134947.

Search strategy and data organization

The Chinese Knowledge Network, Wanfang Database, China Biomedical Database, Pubmed, Embase, and Cochrane Library were searched for RCTs of TCM for the treatment of NPDR in combination with WM before July 6, 2019.

The search used a combined text and MeSH heading search strategy, and the search terms included "early or non-proliferative phase" and "diabetic retinopathy" and "randomized controlled trial or randomized".

Search Strategy: ((((((Non proliferative[Title/Abstract]) OR Non-proliferative [Title/ Abstract]) OR early[Title/Abstract])) AND ((((("Diabetic Retinopathy"[Mesh]) OR Diabetic Retinopathy[Title/Abstract]) OR Diabetic Retinopathies[Title/Abstract]) OR Retinopathies, Diabetic[Title/Abstract]) OR Retinopathy, Diabetic[Title/Abstract]))) AND (randomized controlled trial[Publication Type] OR randomized[Title/Abstract] OR placebo[Title/Abstract]).

The titles and abstracts included in this work were screened by Xuedong An and Fengmei Lian, respectively. Differences were resolved through discussion.

Inclusion criteria

Studies were included if they met the following PICO(S) (participants, intervention, comparators, outcomes (study designs)) criteria:

  1. Participants: The participants had NPDR; no gender and race restrictions.

  2. Intervention: The TCM + WM group was treated with TCM on the basis of WM.

  3. Comparator: The WM group was treated with WM.

  4. Outcome: Direct outcomes included overall efficacy, visual acuity, and retinal fundus examination. Indirect outcomes included fasting blood glucose, 2-h postprandial blood glucose, glycosylated hemoglobin, triglyceride, total cholesterol, high-density lipoprotein, and low-density lipoprotein levels. The safety outcome was adverse events.

  5. Study design: The study type was a randomized controlled trial (blinded or non-blinded).

Clinical studies were independently evaluated by two investigators (Xuedong An and Fengmei Lian) for methods (e.g., correct randomization), interventions, patient selection, efficacy and safety outcomes, to ensure that the studies were eligible for inclusion in our study.

Exclusion criteria

Studies were excluded for: duplicate publication, only abstract or lack of data available, and inability to obtain full-text articles or to extract data for research.

Data extraction

Data, including basic information such as gender, age, duration of disease, basic treatment, major outcome indicators, medication, intervention time, case shedding, and adverse events were collected by Xuedong An and Fengmei Lian.

Assessing the risk of bias and the quality of evidence

The RCTs included in this review were assessed as low, high, or unclear risk of bias using the Cochrane Bias Risk Tool (CRBT), which included random sequence generation, allocation concealment, blinding, incomplete data, selective reporting, and other biases. Xuedong An and Fengmei Lian independently applied the CRBT to assess the risk of bias in each study. Controversial opinions were resolved through discussion.

Statistical analysis of data

All results were analyzed using RevMan 5.2 software provided by the Cochrane Collaboration [14]. The aggregated continuous variable results were analyzed by the mean difference (MD) and 95% confidence interval (CI); the results were summarized and analyzed by relative risk (RR) and 95% CI, while I2 statistics were used to assess heterogeneity. If I2 ≤ 50%, the fixed effect model was used, otherwise the random effect model was employed. In addition, if the primary outcome data were missing or the trial was incomplete, the corresponding author was contacted. We also used the funnel plot to assess potential publication bias according to the Cochrane Handbook [15].

Results

Basic research and quality evaluation

In the literature search, 2938 potentially related articles were found (PubMed: 621, Embase: 436, Cochrane: 1275, China Knowledge Network: 355, Wanfang Database: 143, Chinese Medical Database: 108) (Fig. 1).

Fig. 1.

Fig. 1

Open in a new tab

The study screening process

Finally, 18 studies met the inclusion criteria for this review [16–33], including 1522 patients (763 in the TCM + WM group and 759 in the WM group). Commonly used WM are CD and Yinxingdamo Injection, and commonly used TCM include Qiming Granule, and Compound Xueshuantong Capsule (Table 1). A total of 16 studies reported total efficacy [16–25, 27, 29–33], seven reported vision [17, 19, 20, 23, 26, 29, 31], four, fundus efficacy [17, 26, 28, 29], five, fasting blood glucose (FBG) [17, 26, 28, 29, 33], three reported 2 h-blood glucose (2hPG) [26, 29, 33], five, HbAlc [17, 26, 28, 29, 33], four, triglycerides (TG) [17, 26, 28, 29], five, total cholesterol (TC) [17, 26, 28, 29, 31], three, high density lipoprotein (HDL) [17, 28, 31], and five, low-density lipoprotein (LDL) [17, 26, 28, 29, 31]. Randomization was mentioned in all studies, but only seven studies showed how to generate random distribution sequences [16, 18, 19, 22, 23, 30, 33]. None of the studies presented information related to allocation hiding and blinding methods (Figs. 2, 3).

Table 1.

Basic study characteristics

Study Intervention duration Main indicators Combined treatment Group Number (Number of eyes) Gender
M/F		 Age DR staging (I/II/III) Drug (dose) Case exfoliation
JJ, 2018 [26] 12 w Visual acuity, fundus, blood sugar, blood lipid, inflammatory index Hypoglycemia, hypotension, lipid regulation WM + TCM 30 14/16 58.97 – CD (500 mg, tid) + Yangyin Xiaoyu Mingmu Prescription(100 ml, bid) –
WM 30 15/15 59.2 – CD (500 mg, tid) –
LWJ, 2015 [23] 9 m Visual acuity, symptom score – WM + TCM 38 32/44 57.4 ± 2.8 – CD (2 pills, tid) + Qihuang Mingmu Capsule (4 pills, tid) –
WM 38 CD (2 pills, tid) –
SHL, 2014 [17] 3 m Visual acuity, fundus, blood sugar, blood pressure, blood lipids Control of blood sugar WM + TCM 43 (86) 22/21 50.22 ± 14.82 – CD (2 pills, tid) + Qiming Granule(4.5 g, tid) –
WM 43 (86) 23/20 50.53 ± 11.28 – CD (2 pills, tid) –
WQ, 2018 [22] 3 m Clinical efficacy – WM + TCM 44 18/26 58.4 ± 7.5 – CD (0.5 g,tid) + Qiming Granule (4.5 g, tid) –
WM 44 22/22 57.8 ± 6.2 – CD (0.5 g, tid) –
YXD, 2018 [31] 3 m Visual acuity, mydriasis fundus, anterior segment examination, blood sugar, blood lipid Exercise diet therapy, hypoglycemia WM + TCM 50 24/26 54.63 ± 5.28 19/16/15 CD (0.5 g, tid) + Qiming Granule (1 bag, tid) –
WM 46 25/21 55.27 ± 5.42 18/13/15 CD (0.5 g, tid) –
HCL, 2018 [29] 12 w Fundus score, blood sugar, blood lipid Diet and exercise, hypotension, lipid regulation WM + TCM 40 (79) – 58.95 ± 11.13 18/15/7 CD (0.5 g, tid) + Tangzhiping Prescription (0.5 agents, bid) 3
WM 40 (78) – 58.40 ± 9.21 17/17/6 CD (0.5 g, tid) 2
JHZ, 2014 [19] 6 m Clinical symptoms, visual acuity, fundus, optical coherence tomography, hemorheology Standard diet to control blood sugar WM + TCM 51 31/20 57.8 ± 5.7 – CD (0.5 g, tid) + Ziyin Yiqi Tongluo Recipe (100 ml, bid) –
WM 51 29/22 58.4 ± 6.3 – CD (0.5 g,tid) –
HXD, 2017 [20] 3 m Clinical efficacy, depression of lesion improvement score, visual acuity, TCM symptom score – WM + TCM 40 23/17 52.35 ± 3.11 10/20/10 CD (0.5 g, tid) + Mimeng Flower decoction (0.5 agents, bid) –
WM 40 24/16 52.31 ± 3.07 8/22/10 CD (0.5 g, tid) –
LD, 2018 [30] 3 m Ophthalmic artery, Central retinal artery, Hypoxia-inducible factor-1α、Stromal cell-derived factor 1 Hypoglycemic drugs, diet and exercise WM + TCM 45 27/16 48.34 ± 6.49 21/13/11 CD (250–500 mg, tid) + Compound Xueshuantong Capsule (3 pills, tid) –
WM 45 25/20 48.56 ± 7.64 20/15/10 CD (250–500 mg, tid) –
XLP, 2016 [21] 6 m Visual acuity, slit lamp, intraocular pressure, fundus fluorescein angiography Hypoglycemia, hypotension, lipid regulation WM + TCM 110 (216) 69/41 49.5 ± 5.9 - CD (250–500 mg, tid) + Compound Xueshuantong Capsule (3 pills, tid) –
WM 110 (214) 68/42 50.2 ± 6.4 – CD (250–500 mg, tid) –
PCS, 2013 [25] 3 m Fluorescein fundus angiography, hemorheology, visual field agent flash electroretinogram, overall efficacy Basic treatment of diabetes mellitus WM + TCM 28 (56) 12/16 51.7 ± 10.9 14/22/20 CD (500 mg, bid) + Liangxue Sanyu Decoction (0.5 agents, bid) 7
WM 28(56) 13/15 49.3 ± 8.9 13/26/17 CD (500 mg, bid)
LHY, 2019 [16] 3 m Clinical efficacy, visual acuity – WM + TCM 60 (60) 34/26 49.4 ± 7.8 34/18/8 CD (1 pill, tid) + Compound Xueshuantong Capsule (3 pills, tid) –
WM 60 (60) 32/28 50.3 ± 7.4 34/16/10 CD (1 pill, tid) –
CR, 2011 [18] 3 m Clinical efficacy Diabetic diet, hypoglycemic drugs WM + TCM 30 23/7 50.13 ± 6.74 11/7/12 CD (500 mg, tid) + Yiqi Yangyin Huoxue Prescription (100 ml, tid) –
WM 30 21/9 51.57 ± 5.62 13/12/5 CD (500 mg, tid) –
JCX, 2009 [27] 5 m-1y Fundus examination, visual acuity Hypoglycemia, hypotension and lipid regulation WM + TCM 20 8/12 41–82 6/10/4 Yinxingdamo injection (20 ml, Intravenous drip) + Liuwei Dihuang Decoction –
WM 20 7/13 45–79 5/12/3 Yinxingdamo injection (20 ml, Intravenous drip) –
ZSZ, 2011 [24] 4 m Clinical efficacy Hypoglycemia, lipid regulation, hypotension WM + TCM 20 (38) 18/22 49.35 - CD (500 mg, tid) + TangWangLing (0.5 agents, bid) –
WM 20 (40) CD 500 mg, tid –
YYK, 2016 [28] 3 m Blood sugar, vision, fundus hemorrhage, exudation, microangioma Hypoglycemia, lipid regulation, hypotension WM + TCM 40 22/18 59.85 ± 11.00 15/28/11 CD (0.5 g, tid) + Panax Notoginseng Powder (2 g, tid) -
WM 40 19/21 63.83 ± 9.44 12/30/8 CD (0.5 g, tid) –
WZZ, 2017 [32] 3 m Average visual field sensitivity, related cytokines, efficacy, safety indicators Scientific Dietary Exercise WM + TCM 47 (47) 26/21 54.3 ± 4.9 14/18/15 CD (0.5 g, tid) + Qiming Granule (4.5 g, tid) NA
WM 47 (47) 29/18 54.5 ± 4.8 14/18/15 CD (0.5 g, tid) –
MJP, 2018 [33] 5 m Clinical efficacy, blood sugar, inflammatory factors Symptomatic treatment WM + TCM 27 (34) 16/11 53.02 ± 4.13 9/10/8 CD (3 pills, tid) + Compound Xueshuantong capsule (3 pills, tid) –
WM 27 (34) 15/12 53.08 ± 4.25 10/9/8 CD (3 pills, tid) –
Open in a new tab

Intervention duration, m: month, w: week; gender M/F, M: male, F: female

Fig. 2.

Fig. 2

Open in a new tab

Quality assessment of the included trials-Risk of bias graph

Fig. 3.

Fig. 3

Open in a new tab

Quality assessment of included trials-Risk of bias summary

Main outcomes

Overall efficacy

The overall efficacy in all studies showed homogeneity (I2 = 0%). Statistical data were obtained by using a fixed effect model. The results showed that the overall efficacy of TCM (including Compound Xueshuantong Capsule, Qiming Granule, and others) + WM in the treatment of NPDR was significantly better than that of WM alone [n = 1686, RR 1.24 (1.18, 1.30), P < 0.00001, I2 = 0%] (Fig. 4).

Fig. 4.

Fig. 4

Open in a new tab

Overall efficacy

Vision

There was no difference in the vision level between the TCM + WM group and WM group before intervention (P < 0.27). The results of vision after intervention were heterogeneous (I2 = 95%). Data were analyzed by a random effect model. The results showed that compared with WM alone, TCM (including Qiming Granule and others) + WM treatment of NPDR significantly improved vision [n = 640, MD 0.16 (0.06, 0.27), P = 0.003, I2 = 95%] (Figs. 5, 6).

Fig. 5.

Fig. 5

Open in a new tab

Vision before intervention

Fig. 6.

Fig. 6

Open in a new tab

Vision after intervention

Retinal fundus

The results showed that the retinal fundus effect showed homogeneity (I2 = 0%). Statistical data were obtained by using a fixed effect model. The results showed that compared with WM alone, TCM + WM in the treatment of NPDR fundus significantly improved [n = 553, RR 1.30 (1.19, 1.42), P < 0.00001, I2 = 0%] (Fig. 7).

Fig. 7.

Fig. 7

Open in a new tab

Therapeutic effect on the retinal fundus

FBG

There was no difference in the FBG level between the WM group and the TCM + WM group before intervention (P = 0.16). The results of FBG showed heterogeneity in the two groups after intervention (I2 = 67%). Statistical data were obtained by a random effect model. The results showed that compared with WM alone, TCM + WM could effectively reduce the FBG level in patients with NPDR [n = 360, MD − 0.56 (− 0.91, − 0.22), P = 0.001, I2 = 67%] (Figs. 8, 9).

Fig. 8.

Fig. 8

Open in a new tab

FBG before intervention

Fig. 9.

Fig. 9

Open in a new tab

FBG after intervention

2hPG

There was no difference in the 2hPG level between the WM group and the TCM + WM group (P = 0.71). The results showed that the 2hPG level after intervention showed homogeneity (I2 = 0%). Statistical data were obtained by using a fixed effect model. The results showed that compared with WM alone, TCM + WM could effectively reduce the 2hPG level after intervention in patients with NPDR [n = 194, MD − 1.12 (− 1.62, − 0.61), P < 0.0001, I2 = 0%] (Figs. 10, 11).

Fig. 10.

Fig. 10

Open in a new tab

2hPG before intervention

Fig. 11.

Fig. 11

Open in a new tab

2hPG after intervention

HbAlc

There was no difference in the HbAlc levels between the WM group and the TCM + WM group before intervention (P = 0.16). The results showed that the HbAlc level after intervention showed heterogeneity (I2 = 72%). Data were analyzed by a random effect model. The results showed that TCM + WM could effectively reduce the level of HbAlc compared with WM alone [n = 360, MD − 0.85 (− 1.28, − 0.41), P = 0.0001, I2 = 72%] (Figs. 12, 13).

Fig. 12.

Fig. 12

Open in a new tab

HbAlc before intervention

Fig. 13.

Fig. 13

Open in a new tab

HbAlc after intervention

TG

There was no difference in the TG level between the WM group and the TCM + WM group before intervention (P = 0.53). Studies showed that after intervention, the results of TG showed heterogeneity (I2 = 69%). A random effect model was used to analyze the data. The results showed that compared with WM alone, TCM + WM, but not Qiming Granule (P = 0.23), could effectively reduce TG level in patients with NPDR [n = 220, MD − 0.65 (− 0.79, − 0.51), P < 0.00001, I2 = 0%] (Figs. 14, 15).

Fig. 14.

Fig. 14

Open in a new tab

TG before intervention

Fig. 15.

Fig. 15

Open in a new tab

TG after Intervention

TC

There was no difference in the TC level between the WM group and the TCM + WM group before intervention (P = 0.10). All studies showed that TC after intervention showed heterogeneity (I2 = 91%). A random effect model was used to analyze the data. The results showed that TCM + WM could effectively reduce TC level in patients with NPDR compared with WM alone [n = 220, MD − 0.66 (− 1.05, − 0.27), P = 0.0008, I2 = 71%), but not Qiming Granule (P = 0.15) (Figs. 16, 17).

Fig. 16.

Fig. 16

Open in a new tab

TC before intervention

Fig. 17.

Fig. 17

Open in a new tab

TC after intervention

HDL

There was no difference in the HDL levels between the WM group and the TCM + WM group before intervention (P = 0.96). The results showed that after intervention, HDL showed heterogeneity (I2 = 99%). The data were analyzed by a random effect model. Figure 19 shows no difference in the HDL level between the WM group and the TCM + WM group after intervention [n = 262, MD 0.48 (− 0.46, 1.41), P = 0.32, I2 = 99%] (Figs. 18, 19).

Fig. 19.

Fig. 19

Open in a new tab

HDL after intervention

Fig. 18.

Fig. 18

Open in a new tab

HDL before intervention

LDL

There was no difference in the LDL levels between the WM group and the TCM + WM group before intervention (P = 0.32). The results showed that after intervention, LDL showed heterogeneity (I2 = 87%). Statistical data were obtained by a random effect model. The results showed that compared with WM alone, TCM + WM could effectively reduce LDL levels in patients with NPDR [n = 402, MD − 0.44 (− 0.76, − 0.11), P = 0.009, I2 = 87%] (Figs. 20, 21).

Fig. 20.

Fig. 20

Open in a new tab

LDL before intervention

Fig. 21.

Fig. 21

Open in a new tab

LDL after intervention

Adverse events

Seven studies referred to adverse events [17, 20, 21, 26, 31–33], with only one study reporting two cases of nausea and two cases of loss of appetite in the TCM + WM group, and two cases of stomach discomfort and three cases of loss of appetite in the WM group [20]. There was no difference between the two groups. No follow-up treatment for the adverse reactions was mentioned in any studies.

Publication bias

Funnel charts were used to investigate the publication bias. The funnel charts of the overall efficacy and fundus outcomes were basically symmetrical, indicating potential publication bias. Unpublished research may be considered a factor in publication bias (Figs. 22, 23).

Fig. 22.

Fig. 22

Open in a new tab

Funnel plot of total efficacy

Fig. 23.

Fig. 23

Open in a new tab

Funnel plot of fundus effect

Discussion

The Wisconsin Epidemiologic Study of Diabetic Retinopathy reported that approximately 75% of DM patients developed DR 10 years after diagnosis, while approximately two-thirds of patients with DR at baseline progressed to more severe DR stages, with 20% developing PDR or MDE [34]. With an increasing incidence of DM, the number of patients with DR is expected to increase from 126.6 million in 2010 to 191 million in 2030. According to current estimates, the number of DR with visual threat is expected to increase from 37.3 to 56.3 million [35]. Moreover, the cost of DR is more than half that of non-DR. To sum up, DR has resulted in a tremendous social and economic burden.

At present, the most effective intervention for DR is early screening (i.e. using fundus photography, and fundus fluorescence angiography) and early diagnosis. Studies have shown that standardized, national DR screening can reduce the blindness rate in patients with DM up to 30–50% [36]. At the same time, the DM duration, hyperglycemia and hypertension are the most relevant risk factors for DR. Previous epidemiological and clinical studies have shown that NPDR can reduce the risk and progression of DR by controlling blood sugar and blood pressure levels [37]. Strict blood pressure control can reduce the risk of DR blindness by 47% [38]. However, the current understanding of DR risk factors is still insufficient because current risk factors are not applicable to all patients [39]. For example, HbA1c may account for only 10% of DR risk, blood pressure and serum TC may account for < 10% [40], and family inheritance for about 25–50% [41]. In fact, studies have shown that DR does not occur in some patients with poor blood sugar and/or blood pressure control [42], while other patients with properly controlled blood sugar levels may have severe DR [43], suggesting that other unknown risk factors also play an important role.

In the non-proliferative phase, oral CD and pancreatic kallikrein are commonly used. CD can improve retinal microneuropathy, retinal hemorrhage, exudates, and whole blood viscosity [44], by a mechanism related to the decrease of serum endothelin-1 and high-sensitivity C-reactive protein levels [45, 46].

For PDR, treatments include laser surgery, vitrectomy, tractive retinal detachment, and injection of antiangiogenic factors or application of steroid hormones with DME [39]. Retinal photocoagulation can effectively inhibit and treat retinal neovascularization and reduce the blindness rate by 50–60% [47]. Laser surgery is a destructive treatment, which can only block blindness, but cannot improve vision or fundus lesions of patients. Anti-VEGF injection can lead to intraocular inflammation, hemorrhage, elevated intraocular pressure, and loss of retinal ganglion cells. Corticosteroid hormones prevent vascular leakage by reducing VEGF secretion and release of inflammatory cytokines. However, the incidence of corticosteroid complications is high, most commonly an increase in the intraocular pressure and cataract formation [48]. Therefore, current treatment methods cannot solve this problem with DR treatment.

Because of its simplicity, convenience, cheapness, and testing, TCM has played an indelible role in disease prevention and treatment. In the actual clinical setting, its use in combination with WM can increase the efficacy, reduce adverse events, and even reduce the dosage of WM. For the treatment of DR, Qiming Granule is commonly used, which can relieve retinal hypoxia and ischemia by increasing the retinal blood flow and improving blood circulation [49], and also lower the HbAlc level [50]; Compound Xueshuantong Capsule can protect DR by regulating the Hippo pathway [51], and reducing the VEGF expression, aldose reductase activity, whole blood viscosity and plasma viscosity [52], and lowering blood sugar levels [53].

Based on the screening criteria, 18 RCT studies were included for quality evaluation. The results show that the overall quality of research is low. Compared with WM alone, statistical results showed that TCM + WM had significant effects on clinical efficacy, visual acuity, fundus improvement, and related risk factors (i.e. blood sugar and blood lipid, but not blood pressure). Seven studies discussed the adverse events. Only one study indicated gastrointestinal discomfort, and there was no significant difference between the TCM + WM and the WM groups. No serious adverse events were reported, indicating that addition of TCM to WM for the treatment of NPDR is safe. At the same time, the results showed a great heterogeneity in the statistical analysis of visual acuity, FBG, 2hPG, HbAlC, TG, TC, HDL and LDL, probably due to factors such as fewer patients included in the study and incomplete unification of detection criteria.

Often, clinical efficacy is used to evaluate drug effects. The evaluation criteria for clinical efficacy include visual acuity, fluorescence angiography microangioma, fundus hemorrhage, exudation, edema and other symptoms. For patients with NPDR alone, clinical symptoms are mostly nor present, and they are mainly diagnosed through fundus photography, fluorescence angiography to reveal microangioma, hemorrhage spots, hard exudation, or cotton flocculent spots, while patients with PDR or DME may develop visual impairments. Vision-related findings may be present in patients with DME, but the researchers did not describe such a situation.

Funnel plots of overall efficacy and visual acuity showed basically symmetrical figures, but there was still a publication bias. In conclusion, TCM as an add-on for NPDR is effective, safe, and worthy of clinical application. However, considering the low quality of current research and possible publication bias, caution is needed.

Conclusion

NPDR is the main microvascular complication in patients with DN and needs special attention. Based on the lack of specific treatment for NPDR, there is a need for comprehensive intervention on the disease itself and corresponding risk factors. TCM with multiple targets plays a key role in the treatment of NPDR. The results of our systematic review and meta-analysis of current high-quality clinical studies showed that compared with WM alone, TCM + WM could significantly improve NPDR and also reduce the correlation levels of risk factors such as hyperglycemia or dyslipidemia. However, considering the small sample size in the study, there is a risk of publication bias, and our results should be treated with caution. In the future, we also believe that more high-quality studies should be included to enhance the reliability of the conclusions of this study.

Acknowledgements

Not applicable.

Abbreviations

DR

Diabetic retinopathy

NPDR

Non-proliferative diabetic retinopathy

WM

Western medicine

TCM

Traditional Chinese medicine

RCTs

Randomized controlled trials

DME

Diabetic macular edema

HbAlc

Glycosylated hemoglobin

CD

Calcium dobesilate

VEGF

Vascular endothelial growth factor

PRISMA

Preferred Reporting Project

CRBT

Cochrane Bias Risk Tool

MD

Mean difference

CI

Confidence interval

RR

Relative risk

FBG

Fasting blood glucose

2hPG

2H-blood glucose

TG

Triglycerides

TC

Total cholesterol

HDL

High density lipoprotein

LDL

Low-density lipoprotein

Authors’ contributions

FML and XLT designed the review protocol. DJ and LYD carried out the literature search. FML and XDA contributed to data extraction and quality assessment. RRZ, and SHZ provided statistical supports for meta-analysis. All authors read and approved the final manuscript.

Funding

This work was supported by the National Public Welfare Industry Special (201507001-11), National Traditional Chinese Medicine Administration of Traditional Chinese Medicine Science and Technology Research Project (2016ZX03). The funders had no role in the study design, data collection, data analysis, interpretation, or writing of the report.

Availability of data and materials

The data included original studies and meta-analysis file with TCM + WM for NPDR. The data used to support the findings of this study are available from the corresponding author upon request.

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

Not applicable.

Footnotes

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Xuedong An and De Jin contributed equally and are co-first authors

Contributor Information

Fengmei Lian, Email: lfm565@sohu.com.

Xiaolin Tong, Email: tongxiaolin@vip.163.com.

References

  • 1.Guidelines for the prevention and treatment of type 2 diabetes in China (2017 edition). Chin J Pract Intern Med. 2018;38(04):292–344.
  • 2.Fenwick EK, Pesudovs K, Rees G, Dirani M, Kawasaki R, Wong TY, et al. The impact of diabetic retinopathy: understanding the patient's perspective. Br J Ophthalmol. 2011;95(6):774–782. doi: 10.1136/bjo.2010.191312. [DOI] [PubMed] [Google Scholar]
  • 3.Antonetti DA, Klein R, Gardner TW. Diabetic retinopathy. N Engl J Med. 2012;366(13):1227–1239. doi: 10.1056/NEJMra1005073. [DOI] [PubMed] [Google Scholar]
  • 4.Yau JW, Rogers SL, Kawasaki R, Lamoureux EL, Kowalski JW, Bek T, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012;35(3):556–564. doi: 10.2337/dc11-1909. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Perrone L, Matrone C, Singh LP. Epigenetic modifications and potential new treatment targets in diabetic retinopathy. J Ophthalmol. 2014;2014:789120. doi: 10.1155/2014/789120. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes. 1995;44(8):968–83. [PubMed]
  • 7.Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352(9131):854–65. [PubMed]
  • 8.Zhang HY, Wang JY, Ying GS, Shen LP, Zhang Z. Serum lipids and other risk factors for diabetic retinopathy in Chinese type 2 diabetic patients. J Zhejiang Univ Sci B. 2013;14(5):392–399. doi: 10.1631/jzus.B1200237. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Aiello LP, Edwards AR, Beck RW, Bressler NM, Davis MD, Ferris F, et al. Factors associated with improvement and worsening of visual acuity 2 years after focal/grid photocoagulation for diabetic macular edema. Ophthalmology. 2010;117(5):946–953. doi: 10.1016/j.ophtha.2009.10.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Elman MJ, Qin H, Aiello LP, Beck RW, Bressler NM, Ferris FL, 3rd, et al. Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results. Ophthalmology. 2012;119(11):2312–2318. doi: 10.1016/j.ophtha.2012.08.022. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Yu X, Xu L, Zhou Q, Wu S, Tian J, Piao C, et al. The efficacy and safety of the Chinese herbal formula, JTTZ, for the treatment of type 2 diabetes with obesity and hyperlipidemia: a multicenter randomized, positive-controlled. Open-Label Clin Trial Int J Endocrinol. 2018;2018:9519231. doi: 10.1155/2018/9519231. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Lian F, Wu L, Tian J, Jin M, Zhou S, Zhao M, et al. The effectiveness and safety of a danshen-containing Chinese herbal medicine for diabetic retinopathy: a randomized, double-blind, placebo-controlled multicenter clinical trial. J Ethnopharmacol. 2015;164:71–77. doi: 10.1016/j.jep.2015.01.048. [DOI] [PubMed] [Google Scholar]
  • 13.Stewart LA, Clarke M, Rovers M, Riley RD, Simmonds M, Stewart G, et al. Preferred reporting items for systematic review and meta-analyses of individual participant data: the PRISMA-IPD statement. JAMA. 2015;313(16):1657–1665. doi: 10.1001/jama.2015.3656. [DOI] [PubMed] [Google Scholar]
  • 14.Godlee F. The Cochrane collaboration. BMJ (Clin Res Ed) 1994;309(6960):969–970. doi: 10.1136/bmj.309.6960.969. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Furlan AD, Pennick V, Bombardier C, van Tulder M. 2009 updated method guidelines for systematic reviews in the Cochrane Back Review Group. Spine. 2009;34(18):1929–1941. doi: 10.1097/BRS.0b013e3181b1c99f. [DOI] [PubMed] [Google Scholar]
  • 16.Li H, Zhang Y, Tang M, Yue L, Yan P. Clinical observation on treatment of non-proliferative diabetic retinopathy by integrative Chinese and western medicine. J Hubei Univ Tradit Chin Med. 2019;21(02):72–74. [Google Scholar]
  • 17.Sui H, Yu C, Xue H, Wang R. Clinical observation of Qiming granule combined with calcium hydroxybenzenesulfonate capsule in treating patients with nonproliferative diabetic retinopathy. Chin Med Innov. 2014;11(20):99–102. [Google Scholar]
  • 18.Chen R. Clinical study on treatment of nonproliferative diabetic retinopathy by integrative Chinese and western medicine. Heilongjiang Med Sci. 2011;34(04):73–74. [Google Scholar]
  • 19.Jia H. Clinical study on Ziyin Yiqi Tongluo recipe in treating non-proliferative diabetic retinopathy. Hebei Tradit Chin Med. 2014;36(12):1846–1848. [Google Scholar]
  • 20.Hu D, Ren F, Nan Y. Therapeutic effect of Mimenhuafang combined with calcium hydroxybenzenesulfonate capsule on non-proliferative diabetic retinopathy. Mod J Integr Tradit Chin West Med. 2017;26(18):1945–1947. [Google Scholar]
  • 21.Xiao L. Clinical observation of compound Xueshuantong combined with calcium hydroxybenzenesulfonate in the treatment of nonproliferative diabetic retinopathy. Jilin Med. 2016;37(09):2254–2255. [Google Scholar]
  • 22.Wang Q. Effect of Qiming granule on non-proliferative diabetic retinopathy. Shenzhen J Integr Tradit Chin West Med. 2018;28(10):48–49. [Google Scholar]
  • 23.Li W. Treatment of 38 cases of nonproliferative diabetic retinopathy with Qihuang Mingmu capsule. Hunan J Tradit Chin Med. 2015;31(03):72+83.
  • 24.Zhang S. Clinical observation on treatment of nonproliferative diabetic retinopathy with combination of traditional Chinese medicine and western medicine. Hebei J Tradit Chin Med. 2011;26(02):29–30. [Google Scholar]
  • 25.Cs P, Zz Y. Clinical observation on treatment of nonproliferative diabetic retinopathy with Liangxue Sanyu decoction. Chin J Ophthalmol. 2013;23(03):169–172. [Google Scholar]
  • 26.Jing J. Clinical observation of Yangyin Xiaoyu Mingmu recipe in treating nonproliferative diabetic retinopathy [master's degree]: Nanjing University of Chinese Medicine; 2018.
  • 27.Jiang C, Li S. Clinical observation on treatment of nonproliferative diabetic retinopathy by integrative Chinese and western medicine. J Liaoning Univ Tradit Chin Med. 2009;11(06):179–180. [Google Scholar]
  • 28.Yao Y. Therapeutic effect of Sanqi combined with Shengming on non-proliferative diabetic retinopathy [master's degree]: Nanjing University of Chinese Medicine; 2016.
  • 29.He C, Yin H, Zhang D, Zhang Y, Wang J, Wang S, et al. Effect of glycolipid square on the damage of non-proliferative diabetic retinopathy. China J Tradit Chin Med Inf. 2018;25(09):18–22. [Google Scholar]
  • 30.Liu D, Zhou Q, Zhang Y. Effect of compound Xueshuantong combined with calcium hydroxybenzoate on the levels of HIF-1α and SDF-1 in non-proliferative diabetic retinopathy. Hebei Med. 2018;40(12):1838–1841. [Google Scholar]
  • 31.Yin X. Efficacy and safety evaluation of Qiming Granules combined with calcium dobesilate in the treatment of non-proliferative diabetic retinopathy. Med Theory Pract. 2018;31(01):83–84. [Google Scholar]
  • 32.Wang Z. Qi Ming granule combined with calcium dobesilate in treatment of non-proliferative diabetic retinopathy. Int Eye Sci. 2017;17(4):702–705. [Google Scholar]
  • 33.Ma J. Curative effect evaluation of compound Xueshuantong capsule combined with calcium dobesilate for patients with early diabetic retinopathy. Int Eye Sci. 2018;18(2):305–308. [Google Scholar]
  • 34.Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin epidemiologic study of diabetic retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol. 1984;102(4):520–526. doi: 10.1001/archopht.1984.01040030398010. [DOI] [PubMed] [Google Scholar]
  • 35.Zheng Y, He M, Congdon N. The worldwide epidemic of diabetic retinopathy. Indian J Ophthalmol. 2012;60(5):428–431. doi: 10.4103/0301-4738.100542. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Rohan TE, Frost CD, Wald NJ. Prevention of blindness by screening for diabetic retinopathy: a quantitative assessment. BMJ (Clin Res Ed) 1989;299(6709):1198–1201. doi: 10.1136/bmj.299.6709.1198. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Mohamed Q, Gillies MC, Wong TY. Management of diabetic retinopathy: a systematic review. JAMA. 2007;298(8):902–916. doi: 10.1001/jama.298.8.902. [DOI] [PubMed] [Google Scholar]
  • 38.Wang S, Xu L, Jonas JB, Wong TY, Cui T, Li Y, et al. Major eye diseases and risk factors associated with systemic hypertension in an adult Chinese population. Ophthalmology. 2009;116(12):2373–2380. doi: 10.1016/j.ophtha.2009.05.041. [DOI] [PubMed] [Google Scholar]
  • 39.Wong TY, Cheung CM, Larsen M, Sharma S, Simo R. Diabetic retinopathy. Nat Rev Dis Primers. 2016;2:16012. doi: 10.1038/nrdp.2016.12. [DOI] [PubMed] [Google Scholar]
  • 40.Klein R, Knudtson MD, Lee KE, Gangnon R, Klein BE. The wisconsin epidemiologic study of diabetic retinopathy: XXII the twenty-five-year progression of retinopathy in persons with type 1 diabetes. Ophthalmology. 2008;115(11):1859–1868. doi: 10.1016/j.ophtha.2008.08.023. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Arar NH, Freedman BI, Adler SG, Iyengar SK, Chew EY, Davis MD, et al. Heritability of the severity of diabetic retinopathy: the FIND-Eye study. Invest Ophthalmol Vis Sci. 2008;49(9):3839–3845. doi: 10.1167/iovs.07-1633. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Keenan HA, Costacou T, Sun JK, Doria A, Cavellerano J, Coney J, et al. Clinical factors associated with resistance to microvascular complications in diabetic patients of extreme disease duration: the 50-year medalist study. Diabetes Care. 2007;30(8):1995–1997. doi: 10.2337/dc06-2222. [DOI] [PubMed] [Google Scholar]
  • 43.Zhang L, Krzentowski G, Albert A, Lefebvre PJ. Risk of developing retinopathy in Diabetes Control and Complications Trial type 1 diabetic patients with good or poor metabolic control. Diabetes Care. 2001;24(7):1275–1279. doi: 10.2337/diacare.24.7.1275. [DOI] [PubMed] [Google Scholar]
  • 44.Zhang X, Liu W, Wu S, Jin J, Li W, Wang N. Calcium dobesilate for diabetic retinopathy: a systematic review and meta-analysis. Sci China Life Sci. 2015;58(1):101–107. doi: 10.1007/s11427-014-4792-1. [DOI] [PubMed] [Google Scholar]
  • 45.Kumar B, Gupta SK, Saxena R, Srivastava S. Current trends in the pharmacotherapy of diabetic retinopathy. J Postgrad Med. 2012;58(2):132–139. doi: 10.4103/0022-3859.97174. [DOI] [PubMed] [Google Scholar]
  • 46.Javadzadeh A, Ghorbanihaghjo A, Adl FH, Andalib D, Khojasteh-Jafari H, Ghabili K. Calcium dobesilate reduces endothelin-1 and high-sensitivity C-reactive protein serum levels in patients with diabetic retinopathy. Mol Vis. 2013;19:62–68. [PMC free article] [PubMed] [Google Scholar]
  • 47.Palanker D, Blumenkranz MS. Panretinal photocoagulation for proliferative diabetic retinopathy. Am J Ophthalmol. 2012;153(4):780–781. doi: 10.1016/j.ajo.2012.01.001. [DOI] [PubMed] [Google Scholar]
  • 48.Bandello F, Preziosa C, Querques G, Lattanzio R. Update of intravitreal steroids for the treatment of diabetic macular edema. Ophthalmic Res. 2014;52(2):89–96. doi: 10.1159/000362764. [DOI] [PubMed] [Google Scholar]
  • 49.Luo XX, Duan JG, Liao PZ, Wu L, Yu YG, Qiu B, et al. Effect of qiming granule on retinal blood circulation of diabetic retinopathy: a multicenter clinical trial. Chin J Integr Med. 2009;15(5):384–388. doi: 10.1007/s11655-009-0384-5. [DOI] [PubMed] [Google Scholar]
  • 50.Cao P. Changes of retinal vessel diameter in diabetic microvascular complications and the effect of Qiming granule intervention [Doctor]: Chengdu University of Traditional Chinese Medicine; 2016.
  • 51.Hao GM, Lv TT, Wu Y, Wang HL, Xing W, Wang Y, et al. The Hippo signaling pathway: a potential therapeutic target is reversed by a Chinese patent drug in rats with diabetic retinopathy. BMC Complement Altern Med. 2017;17(1):187. doi: 10.1186/s12906-017-1678-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Duan H, Huang J, Li W, Tang M. Protective effects of fufang xueshuantong on diabetic retinopathy in rats. Evid-Based Complement Altern Med. 2013;2013:408268. doi: 10.1155/2013/408268. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Xia S, Hu S, Liao Y, Li S. Clinical effect analysis of compound Xueshuantong capsule in treating patients with diabetic retinopathy. Tradit Chin Med Clin Res. 2019;11(11):61–64. [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Availability Statement

The data included original studies and meta-analysis file with TCM + WM for NPDR. The data used to support the findings of this study are available from the corresponding author upon request.

Articles from Chinese Medicine are provided here courtesy of BMC

RESOURCES